WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy
Ver el documentoCYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism
Ver el documentoDIETHYL-STILBESTROL - Gynaecological and obstetric complications after in utero exposure
Ver el documentoEPHEDRA - Moves to reduce risks of ephedra-containing products
Ver el documentoFLUTICASONE PROPIONATE - Reports of adrenal crisis
Ver el documentoGRAPEFRUIT JUICE - Revised advice from ADRAC
Ver el documentoHORMONE REPLACEMENT THERAPY (HRT) - Risk of dementia
Ver el documentoOMEPRAZOLE, RABEPRAZOLE - Reports of interstitial nephritis
Ver el documentoROFECOXIB, CELECOXIB - Case reports support causal association with liver toxicity
Ver el documentoROSIGLITA-ZONE, PIOGLITAZONE - Adverse reactions update
Ver el documentoSOMATROPIN - Not to be authorized for AIDS-related wasting syndrome
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

CYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism

Canada. The combination product of cyproterone and ethinylestradiaol (Diane-35) is prescribed in the treatment of androgen related conditions such as severe acne or hirsutism in women. As with all estrogen/progestogen combination products, the combination of cyproterone and ethinyl-estradiol (Diane-35) is associated with an increased risk of venous thromboembolism. This product is therefore contraindicated in women with thrombophlebitis, thromboembolic disorders or a history of these conditions. Some published studies suggest that users of this combination product (Diane-35) may have an elevated risk of venous thromboembolic events compared to users of combination oral contraceptives. The combination of cyproterone and ethinylestradiol (Diane-35) should not be prescribed for the sole purpose of contraception. And, during treatment with this combination, other oral contraceptives should not be used. This information has been sent to all healthcare professionals by Berlex Canada Inc, in consultation with Health Canada.

Reports in WHO-file: Thromboembolism 3, thrombosis 43

Reference:
‘Dear Healthcare Professional’ letter from Berlex Canada Inc, 10 Apr 2003. Available from URL: http://www.hc-sc.gc.ca

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019